by Ubaka Ogbogu | Jan 13, 2011
A couple of significant updates to report on from the ethics and law arena: On December 22, 2010, the Supreme Court of Canada (SCC) released its long-awaited judgment in the Reference re: Assisted Human Reproduction Act case involving a constitutional challenge...
by Stem Cell Network | Jan 12, 2011
In an article in the Globe and Mail this past weekend, reporter Carolyn Abraham provided an interesting and under-reported glimpse into the cosmetics industry use of stem cells to market their products. She notes: “In science, ‘stem cell’ has been...
by Ubaka Ogbogu | Jan 4, 2011
In March 2009, in his remarks at the signing of an Executive Order to reverse the Bush-era stem cell research funding restrictions, President Obama directed John P. Holdren, Director of the Office of Science and Technology Policy, to “develop a strategy for restoring...
by Stem Cell Network | Dec 29, 2010
Earlier this month, the Honourable Tony Clement, Minister of Industry, announced the establishment of the Centre for the Commercialization of Regenerative Medicine (CCRM) with a $15 million initial investment. The CCRM will be based in Toronto and is one of five new...
by Ubaka Ogbogu | Dec 16, 2010
President Obama’s Commission on the Study of Bioethical Issues today released a report of its ethical investigation and recommendations for oversight of the emerging field of synthetic biology. The report responds to a charge to the Commission issued by the President...
by Chris Kamel | Dec 9, 2010
Induced pluripotent stem (iPS) cells are generally created by the expression of a small number of key genes to reprogram adult cells into an undifferentiated, pluripotent state. Because some of the transcription factors used for reprogramming are oncogenes, as well as...
Comments